Skip to content
sellWeak cluster of 410b5-1 plan

David C Hastings sold $73k of ABUS

Chief Financial Officer at Arbutus Biopharma Corp. 22,183 shares at an average of $3.28, traded Feb 4, 2025, filed Feb 5, 2025.

Warning score
30
Value
$73k
22,183 shares
Holdings after
159,724
-12% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    CFO
    +22
  • Trade size
    $73k at market
    +8
  • Share of holdings sold
    Sold 12% of holdings
    +5
  • Cluster
    4 insiders selling within 14 days
    +15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -7.8%, 3m -8.4%, 6m -3.3%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

ABUSOct 9, 2026 · close 4.22
Since filing Feb 5, 2025: +17.5%SPY +31.4% · excess -13.8%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001447028-25-000040, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Feb 4, 2025SOpen-market sale
Common Shares10b5-1
-22,183$3.28$73k159,724Feb 5, 2025

Related signals

Other insiders at Arbutus Biopharma Corp and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
21Weak
ABUSsell 410b5-1
Arbutus Biopharma Corp
J. Christopher Naftzger
General Counsel and CCO
$37k
11,333 shares
-12%
29Weak
ABUSsell 410b5-1
Arbutus Biopharma Corp
Michael J. McElhaugh
Interim President & CEO
$78k
23,790 shares
-2%
23Weak
ABUSsell 410b5-1
Arbutus Biopharma Corp
Karen Sims
Chief Medical Officer
$64k
19,348 shares
-15%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

David C Hastings sold $73k of ABUS | InsiderTell